Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v16-EN | Version v6-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2023-09-01 | 2023-03-30 |
| Drug Identification Number | 02506270 | 02506270 |
| Brand name | APO-SITAGLIPTIN/METFORMIN XR | APO-SITAGLIPTIN/METFORMIN XR |
| Common or Proper name | SITAGLIPTAN PHOSPHATE/METFORMIN | SITAGLIPTAN PHOSPHATE/METFORMIN |
| Company Name | APOTEX INC | APOTEX INC |
| Ingredients | METFORMIN HYDROCHLORIDE SITAGLIPTIN | METFORMIN HYDROCHLORIDE SITAGLIPTIN |
| Strength(s) | 500MG 50MG | 500MG 50MG |
| Dosage form(s) | TABLET (EXTENDED-RELEASE) | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL | ORAL |
| Packaging size | 60 BTL | 60 BTL |
| ATC code | A10BD | A10BD |
| ATC description | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
| Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
| Anticipated start date | ||
| Actual start date | 2023-03-02 | 2023-03-02 |
| Estimated end date | 2023-09-30 | 2023-04-28 |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Product on allocation due to increased demand | Product on allocation due to increased demand |
| Health Canada comments |